These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

108 related items for PubMed ID: 8557988

  • 1. B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct.
    Matulonis U, Dosiou C, Freeman G, Lamont C, Mauch P, Nadler LM, Griffin JD.
    J Immunol; 1996 Feb 01; 156(3):1126-31. PubMed ID: 8557988
    [Abstract] [Full Text] [Related]

  • 2. Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic anti-tumor immunity against different mouse tumors.
    Martin-Fontecha A, Cavallo F, Bellone M, Heltai S, Iezzi G, Tornaghi P, Nabavi N, Forni G, Dellabona P, Casorati G.
    Eur J Immunol; 1996 Aug 01; 26(8):1851-9. PubMed ID: 8765031
    [Abstract] [Full Text] [Related]

  • 3. Rejection of MHC class II-transfected tumor cells requires induction of tumor-encoded B7-1 and/or B7-2 costimulatory molecules.
    Baskar S, Clements VK, Glimcher LH, Nabavi N, Ostrand-Rosenberg S.
    J Immunol; 1996 May 15; 156(10):3821-7. PubMed ID: 8621919
    [Abstract] [Full Text] [Related]

  • 4. Induction of therapeutic T-cell immunity by tumor targeting with soluble recombinant B7-immunoglobulin costimulatory molecules.
    Moro M, Gasparri AM, Pagano S, Bellone M, Tornaghi P, Veglia F, Corti A, Casorati G, Dellabona P.
    Cancer Res; 1999 Jun 01; 59(11):2650-6. PubMed ID: 10363988
    [Abstract] [Full Text] [Related]

  • 5. B7-1 and interleukin 12 synergistically induce effective antitumor immunity.
    Coughlin CM, Wysocka M, Kurzawa HL, Lee WM, Trinchieri G, Eck SL.
    Cancer Res; 1995 Nov 01; 55(21):4980-7. PubMed ID: 7585539
    [Abstract] [Full Text] [Related]

  • 6. Immunogene therapy against mouse leukemia using B7 molecules.
    Takahashi T, Hirano N, Takahashi T, Chiba S, Yazaki Y, Hirai H.
    Cancer Gene Ther; 2000 Jan 01; 7(1):144-50. PubMed ID: 10678367
    [Abstract] [Full Text] [Related]

  • 7. Specificity and longevity of antitumor immune responses induced by B7-transfected tumors.
    Townsend SE, Su FW, Atherton JM, Allison JP.
    Cancer Res; 1994 Dec 15; 54(24):6477-83. PubMed ID: 7527298
    [Abstract] [Full Text] [Related]

  • 8. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine.
    Guinn BA, DeBenedette MA, Watts TH, Berinstein NL.
    J Immunol; 1999 Apr 15; 162(8):5003-10. PubMed ID: 10202049
    [Abstract] [Full Text] [Related]

  • 9. The capacity of the natural ligands for CD28 to drive IL-4 expression in naïve and antigen-primed CD4+ and CD8+ T cells.
    Bian Y, Hiraoka S, Tomura M, Zhou XY, Yashiro-Ohtani Y, Mori Y, Shimizu J, Ono S, Dunussi-Joannopoulos K, Wolf S, Fujiwara H.
    Int Immunol; 2005 Jan 15; 17(1):73-83. PubMed ID: 15569772
    [Abstract] [Full Text] [Related]

  • 10. Host B7-1 and B7-2 costimulatory molecules contribute to the eradication of B7-1-transfected P815 tumor cells via a CD8+ T cell-dependent mechanism.
    La Motte RN, Sharpe AH, Bluestone JA, Mokyr MB.
    J Immunol; 1999 Apr 15; 162(8):4817-23. PubMed ID: 10202025
    [Abstract] [Full Text] [Related]

  • 11. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity.
    Todo T, Martuza RL, Dallman MJ, Rabkin SD.
    Cancer Res; 2001 Jan 01; 61(1):153-61. PubMed ID: 11196154
    [Abstract] [Full Text] [Related]

  • 12. Induction and maintenance of T-cell response to a nonimmunogenic murine mesothelioma cell line requires expression of B7-1 and the capacity to upregulate class II major histocompatibility complex expression.
    Leong C, Marley J, Loh S, Robinson B, Garlepp M.
    Cancer Gene Ther; 1996 Jan 01; 3(5):321-30. PubMed ID: 8894251
    [Abstract] [Full Text] [Related]

  • 13. Costimulation of IL-4 production by murine B7-1 and B7-2 molecules.
    Natesan M, Razi-Wolf Z, Reiser H.
    J Immunol; 1996 Apr 15; 156(8):2783-91. PubMed ID: 8609397
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Importance of B7-1-expressing host antigen-presenting cells for the eradication of B7-2 transfected P815 tumor cells.
    La Motte RN, Sharpe AH, Bluestone JA, Mokyr MB.
    J Immunol; 1998 Dec 15; 161(12):6552-8. PubMed ID: 9862681
    [Abstract] [Full Text] [Related]

  • 17. CD28/B7 interactions are required for sustaining the graft-versus-leukemia effect of delayed post-bone marrow transplantation splenocyte infusion in murine recipients of myeloid or lymphoid leukemia cells.
    Blazar BR, Taylor PA, Boyer MW, Panoskaltsis-Mortari A, Allison JP, Vallera DA.
    J Immunol; 1997 Oct 01; 159(7):3460-73. PubMed ID: 9317145
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Functional consequences of dysregulated B7-1 (CD80) and B7-2 (CD86) expression in B or T lymphocytes of transgenic mice.
    Van Parijs L, Sethna MP, Schweitzer AN, Borriello F, Sharpe AH, Abbas AK.
    J Immunol; 1997 Dec 01; 159(11):5336-44. PubMed ID: 9548473
    [Abstract] [Full Text] [Related]

  • 20. Human fibroblasts transduced with CD80 or CD86 efficiently trans-costimulate CD4+ and CD8+ T lymphocytes in HLA-restricted reactions: implications for immune augmentation cancer therapy and autoimmunity.
    Smythe JA, Fink PD, Logan GJ, Lees J, Rowe PB, Alexander IE.
    J Immunol; 1999 Sep 15; 163(6):3239-49. PubMed ID: 10477593
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.